Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens |
| |
| Affiliation: | 1. University of Minnesota, Minneapolis, MN, United States of America;2. University of Cincinnati College of Medicine, Cincinnati, OH, United States of America;3. Massachusetts General Hospital, Boston, MA, United States of America;4. University of Virginia, Charlottesville, VA, United States of America;5. CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, WI, United States of America;6. Rush University Medical Center, Chicago, IL, United States of America;7. Center for International Blood and Marrow Transplant, Milwaukee, WI, United States of America;8. University of North Carolina, Chapel Hill, NC, United States of America;9. Medical College of Wisconsin, Milwaukee, WI, United States of America;10. College of Medicine, Mayo Clinic, Phoenix, AZ, United States of America |
| |
| Abstract: | Allogeneic hematopoietic stem cell transplantation mortality has declined over the years, though prevention and management of treatment-related toxicities and post-transplant complications remains challenging. Applications of pharmacogenomic testing can potentially mitigate adverse drug outcomes due to interindividual variability in drug metabolism and response. This review summarizes clinical pharmacogenomic applications relevant to hematopoietic stem cell transplantation, including antifungals, immunosuppressants, and supportive care management, as well as emerging pharmacogenomic evidence with conditioning regimens. |
| |
| Keywords: | Pharmacogenomics Pharmacogenetics Supportive care Bone marrow transplant Hematopoietic stem cell transplantation Allogeneic transplantation |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
